Moderna Inc. ($MRNA) Stock Forecast: Down 5.0% Today

What is Moderna Inc.?

Moderna (NASDAQ: MRNA) is a biotechnology company recognized for its mRNA-based vaccines, notably for COVID-19, and is closely linked to the healthcare and pharmaceutical industries.

Why is Moderna Inc. going down?

MRNA stock is down 5.0% on Aug 25, 2025 19:46

• Today's decline in Moderna's stock price could be linked to concerns regarding the Trump administration's contemplation of removing COVID-19 vaccines from the market. This uncertainty may have prompted investors to sell, influenced by the unsettling news.
• The approval of Moderna's updated Spikevax vaccine by Health Canada could have been viewed positively. Despite this, the broader market sentiment, undulated by negative reports, overshadowed this favorable development.
• The ambiguity and contradictory information about the future of COVID-19 vaccines and their potential impact on Moderna's market position likely contributed to the bearish trend in the stock today.
• Investors are likely keeping a close watch on any updates regarding vaccine regulations and approvals, as well as Moderna's strategies to navigate the evolving dynamics of the healthcare sector.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Trump Administration Plans To Pull COVID-19 Vaccines Off Market 'Within Months' - Moderna ( NASDAQ:MRNA ) , BioNTech ( NASDAQ:BNTX )

RFK Jr.'s adviser says COVID-19 vaccines could be pulled from the U.S. market within months. MIT professor critical of mRNA shots named to lead federal vaccine task force. See the seasonal trading strategy that's beating the S&P 500 by 6X this year. Details here →

https://www.benzinga.com/markets/large-cap/25/08/47316871/trump-administration-plans-to-pull-covid-19-vaccines-off-market-within-months

Moderna Stock Is Trading Higher Friday: What's Going On? - Moderna ( NASDAQ:MRNA )

Health Canada approves Moderna's updated Spikevax vaccine targeting the LP.8.1 variant for individuals six months and older. All pre-filled syringe doses for Canada are produced domestically for the first time, with Canadian-made supply available this fall. The market is reacting to Powell's ...

https://www.benzinga.com/trading-ideas/movers/25/08/47289361/moderna-stock-is-trading-higher-friday-whats-going-on

Trending Today

Aave ($AAVE) Crypto Forecast: Down 5.2% Today

Ondo ($ONDO) Crypto Forecast: Down 5.3% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.3% Today

Affirm Holdings Inc. ($AFRM) Stock Forecast: Up 5.2% Today

Illumina Inc. ($ILMN) Stock Forecast: Up 5.2% Today

Tilray Inc. ($TLRY) Stock Forecast: Up 5.3% Today

Shoals Technologies Group Inc. ($SHLS) Stock Forecast: Up 5.1% Today

Duolingo Inc. ($DUOL) Stock Forecast: Down 5.0% Today

Teleflex Incorporated ($TFX) Stock Forecast: Down 5.1% Today

Opendoor Technologies Inc. ($OPEN) Stock Forecast: Down 8.1% Today

Moderna Inc. Price History

01.07.2025 - MRNA Stock was down 13.0%

• Moderna reported a Q2 loss per share, surpassing expectations, which likely disappointed investors.
• The decline in revenue, mainly attributed to decreased COVID-19 vaccine sales, likely influenced the stock's bearish movement.
• The revised revenue forecast and company downsizing announcement may have heightened concerns about Moderna's future growth prospects.
• Overall, the market responded negatively to Moderna's financial results and the challenges faced in the COVID-19 vaccine sector, resulting in the stock's downward movement.

13.07.2025 - MRNA Stock was up 5.1%

• Moderna's stock showed a bullish movement attributed to investors with significant capital displaying a positive sentiment towards the company.
• Speculations surrounding the potential action of the FDA regarding the authorization of Pfizer's COVID vaccine for young children could indirectly benefit Moderna by increasing reliance on alternative vaccine providers.
• The bullish stance taken by whales (large investors) on Moderna added to the positive market sentiment and contributed to the stock's notable upward movement.

25.07.2025 - MRNA Stock was down 5.0%

• Today's decline in Moderna's stock price could be linked to concerns regarding the Trump administration's contemplation of removing COVID-19 vaccines from the market. This uncertainty may have prompted investors to sell, influenced by the unsettling news.
• The approval of Moderna's updated Spikevax vaccine by Health Canada could have been viewed positively. Despite this, the broader market sentiment, undulated by negative reports, overshadowed this favorable development.
• The ambiguity and contradictory information about the future of COVID-19 vaccines and their potential impact on Moderna's market position likely contributed to the bearish trend in the stock today.
• Investors are likely keeping a close watch on any updates regarding vaccine regulations and approvals, as well as Moderna's strategies to navigate the evolving dynamics of the healthcare sector.

24.05.2025 - MRNA Stock was up 5.4%

• Moderna's stock had a strong bullish movement today, closing at $25.90 with a +1.97% shift.
• The bullish movement could be attributed to positive developments related to the company's pipeline or vaccine distribution.
• Despite the bullish movement, there are indications that deep-pocketed investors have taken a bearish stance on Moderna, as revealed by options records. This contrasting sentiment from big money investors could be due to concerns about future growth prospects or market conditions.

31.06.2025 - MRNA Stock was down 5.1%

• Moderna's stock saw a decline today for the following reasons:
• The announcement of a 10% reduction in workforce hints at challenges affecting COVID-19 vaccine sales and regulatory issues, which could impact the company's revenue.
• The decrease in Covid shot sales and implementation of cost-cutting strategies suggest a shift in the company's growth path, dampening investor confidence.
• Concerns about Moderna's Q2 earnings report are looming, with anticipated drops in Spikevax sales and crucial pipeline advancements potentially fueling the negative stock trajectory.

10.06.2025 - MRNA Stock was up 5.1%

• Moderna's stock (MRNA) saw a notable uptrend subsequent to receiving full approval from the FDA for its COVID-19 vaccine for children aged 6 months and above.
• The extended approval for this younger age demographic suggests a wider market scope for Moderna's vaccine, fostering enhanced investor confidence and propelling the stock price upwards.
• This favorable development underscores Moderna's ongoing success in diversifying its vaccine portfolio and combatting the global health crisis, contributing to the bullish trend in the stock today.

10.06.2025 - MRNA Stock was up 5.4%

• Moderna (MRNA) stock showed significant bullish movement.
• The positive market trend may be linked to potential developments in Moderna's vaccines and therapeutics pipeline.
• Investors are likely responding favorably to updates on Moderna's ongoing research and development activities, leading to an increase in stock price.
• The bullish movement could also be influenced by general market positivity and investor trust in the biotechnology industry.

02.06.2025 - MRNA Stock was up 5.6%

• Moderna's stock (MRNA) witnessed a noticeable upward trend in the market today.
• The favorable market response is linked to the recent announcement regarding Moderna's mRNA flu vaccine, mRNA-1010, displaying 26.6% higher efficacy in adults aged 50 and above compared to conventional flu shots.
• Investors responded positively to the encouraging vaccine trial results, signaling Moderna's potential to maintain its forefront position in mRNA-based vaccine research.
• This development highlights Moderna's ongoing advancements in the healthcare sector, bolstering investor confidence and contributing to the stock's uptick.

29.06.2025 - MRNA Stock was down 5.4%

• Despite high expectations for Moderna's Q2 performance, the stock experienced a strong bearish movement today.
• The sharp decline in Spikevax sales and RSV uptake could have contributed to the bearish market movement.
• The market whales' bullish stance on MRNA options may not have been enough to counterbalance the disappointing Q2 results, leading to the bearish trend.
• Investors were anticipating a potential earnings beat from Moderna, but the actual results may have fallen short of these expectations, causing the bearish movement in the stock price.

01.07.2025 - MRNA Stock was down 9.9%

• Moderna (MRNA) stock experienced a bearish movement due to several factors:
• Moderna reported a Q2 loss of $2.13 per share, although it beat revenue estimates. The decrease in revenue by 41% from 2024 was mainly attributed to a decline in COVID-19 vaccine sales.
• Novavax's stock also dipped, possibly contributing to negative sentiment in the vaccine sector after Moderna's disappointing Q2 results.
• Despite some bullish options trading trends observed, the overall market sentiment was impacted by Moderna's financial performance and reduced revenue outlook for 2025.
• The combination of a loss in revenue, reduced revenue outlook, and a general downtrend in the vaccine sector likely led to the bearish movement in Moderna's stock.

08.06.2025 - MRNA Stock was up 5.3%

• MRNA stock rose significantly following the CDC's decision to broaden recommendations for RSV vaccine to high-risk adults aged 50-59.
• The expanded guidance is anticipated to enhance the market accessibility of Moderna's RSV vaccine, mResvia, increasing investor confidence and boosting the stock price.
• This favorable development showcases Moderna's ongoing success in utilizing its advanced technology to address crucial healthcare needs, further establishing its position as a prominent player in the biotech industry.

15.06.2025 - MRNA Stock was down 5.1%

• Moderna's stock saw a decline, even though it recently received full FDA approval for its COVID-19 vaccine in pediatric patients.
• The market response could be linked to general market trends or profit-taking following recent stock increases.
• Investors may be considering various factors like market conditions and potential competition in the vaccine sector.
• Despite the decrease, Moderna's future in biotechnology appears promising, particularly given its successful vaccine innovations.